SCHEMBL31312432

SCHEMBL31312432

Cc1ccc(NC(=O)c2cc(C(N)=O)cnn2)cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 8/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
CXCR2 P25025 2/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 2/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
SIRT3 Q9NTG7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31312382 0.83 LRRK2 (0.38) BACE1NPC1RAB9AMAPTGAA
SCHEMBL31312305 0.83 RAF1 (0.49) RAF1BRAFKMT2ALIPE
SCHEMBL28630762 0.83 RAF1 (0.49) RAF1BRAFKMT2ALIPE
SCHEMBL31636286 0.82 RAF1 (0.39) BACE1NPC1RAB9AMAPTGAA
SCHEMBL25421949 0.76 SLC6A3 (0.43) CA1CA2CA9CXCR2NPC1
SCHEMBL16533843 0.76 KMT2A (0.46) CA1CA2CA9CXCR2NPC1
SCHEMBL13197996 0.76 NPC1 (0.57) CA1CA2CA9NPC1RAB9A
SCHEMBL12797362 0.73 ALDH1A1 (0.43) CA1CA2CA9NPC1RAB9A
SCHEMBL1347543 0.73 MAPK14 (0.39) CA1CA2CA9MAPTKDM4E
SCHEMBL19529424 0.73 CNR1 (0.55) NPC1RAB9AMAPTBRAFMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727922-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
WO-2025137105-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2025-06-26 WO disclosed
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2025-06-26 US disclosed
WO-2024263460-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2024-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206729-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF BRAF, MAP2K2, MAP2K1 BACE1 3753/4885CA1 4269/4885CA2 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.